Welcome to our dedicated page for CANNAPHARMARX SEC filings (Ticker: CPMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CANNAPHARMARX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CANNAPHARMARX's regulatory disclosures and financial reporting.
CannaPharmaRx, Inc. (CPMD), a Canadian cannabis cultivator, reported higher revenue but continued heavy losses and liquidity stress for the quarter and six months ended June 30, 2026. Revenue rose to $276,218 for the quarter and $903,680 for the first half of 2026, largely from related-party sales to Cantek.
The company still generated a gross loss of $138,446 for the quarter and $547,899 year-to-date, and recorded a net loss of $1,909,042 for the quarter and $2,291,063 for six months. Cash was only $555 with a working capital deficiency of $31.2 million and accumulated deficit of $114.6 million, and management explicitly states there is substantial doubt about its ability to continue as a going concern.
Operations are highly dependent on related parties: loans payable to related parties total $13.4 million, royalty and lease obligations are in default with Koze and Formosa (with Koze temporarily forbearing from enforcing its security over the main operating subsidiary), and multiple secured borrowings are in default, exposing assets to potential seizure. Insurance coverage has lapsed, and several legal matters and judgments are outstanding, while the company also continues to dilute shareholders through equity-for-debt settlements.
CannaPharmaRX, Inc. notified regulators that its Form 10-Q for the quarter ended June 30, 2026 will be filed late under Form 12b-25 due to delays in obtaining and compiling required information, which it states could not be resolved without unreasonable effort and expense. The company expects to file the report no later than the fifth calendar day after the original due date. For the three and six months ended June 30, 2026, it reported revenues of $276,218 and $903,680, compared with $231,608 and $566,927 for the same 2025 periods, reflecting higher cannabis sales volumes and increased sales to existing customers. Over the same periods, it recorded gross losses of $138,446 and $547,899, improved from gross losses of $621,210 and $1,123,817 a year earlier, mainly due to higher revenue and lower inventory impairment charges.
CannaPharmaRx, Inc. reported Q1 2026 revenue of $627,462, up from $335,319 a year earlier, but operations remained unprofitable with a net loss of $382,021 and a gross loss of $409,453.
Cash was only $633 at March 31, 2026, against a working capital deficiency of $30,556,522, total liabilities of $36,850,622, and a shareholders’ deficit of $30,269,888. Management states there is substantial doubt about the company’s ability to continue as a going concern and plans to rely on debt and equity financings, largely from related parties.
All Q1 revenue came from related-party sales, mainly to an affiliate owned by Koze. The company is in default under a security and royalty agreement tied to its main operating subsidiary, and Koze has agreed to forbear exercising its security over that subsidiary until May 31, 2026. Multiple loans to Koze, Mr. Tal and Formosa, royalty obligations, legal disputes, and lapsed insurance further strain liquidity even as the Cremona facility ramps cannabis production and targets European markets.
CannaPharmaRX, Inc. notified the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 under Rule 12b-25 and intends to file the Form 10-Q within five calendar days of the prescribed due date. The notice cites delays in obtaining and compiling required information.
The filing discloses revenues of $627,462 for the three months ended March 31, 2026 versus $335,319 in 2025, and gross losses of $409,453 and $502,607, respectively; the company attributes revenue growth to expansion of its medical cannabis product line and new retail partners.
CannaPharmaRx, Inc. is a Canada-based cannabis cultivator focused on premium dried flower, operating a 55,000 square foot indoor facility in Cremona, Alberta. The company targets medical markets in Canada, Germany, Israel and other EU countries and seeks EU-GMP certification to export directly into Europe.
For the year ended December 31, 2025, CannaPharmaRx generated approximately $1.4 million in revenue but reported a net loss of $11,131,448, an accumulated deficit of $112.3 million, cash of $1,804, and a working capital deficit of $30,278,570. Operating cash flow was negative $789,102, and management states there is substantial doubt about the company’s ability to continue as a going concern without new financing.
The company fully impaired a $4,518,127 investment in LTB Management, concluding expected cash flows were negative. All outstanding convertible notes were past maturity, triggering penalty provisions that produced an accrued penalty liability of $735,002. Its main operating subsidiary is in default under a royalty and security agreement with Koze Investments, which has agreed to forbear enforcing its security over the subsidiary’s equity until May 31, 2026.
At June 30, 2025, the aggregate market value of non‑affiliate equity was $2,583,755. As of March 31, 2026, there were 678,501,405 common shares outstanding, traded on the OTC expert market under the symbol CPMD, with the company highlighting thin liquidity, penny share status, significant dilution risk and heavy regulatory and competitive pressures in the cannabis sector.
CannaPharmaRX, Inc. reported that director Rick Orman resigned from its Board of Directors effective immediately on January 8, 2026. The company states that his resignation did not result from any dispute or disagreement with the company or the Board regarding operations, policies, or practices.
The company also noted that on January 12, 2026, it issued a press release providing corporate updates and outlining its 2026 growth strategy, which has been furnished as an exhibit to this report.
CannaPharmaRX, Inc. reports that the BC Securities Commission has revoked its failure-to-file cease trade order, effective December 12, 2025, after the company completed its previously delinquent Canadian and U.S. filings. The order had stemmed from missing annual financial statements and related disclosures for the year ended December 31, 2022.
Despite this regulatory step, the company highlights substantial doubt about its ability to continue as a going concern. It reports a working capital deficiency of $27,009,769 and related party debt of $10,762,898 with accrued interest of $3,248,127 as of September 30, 2025. Management’s plan includes negotiating debt restructurings, seeking additional working capital, ramping cannabis production at its Cremona, Alberta facility beyond the current six of ten operating grow rooms, and expanding into European markets such as Germany and Israel, supported by a planned EU-GMP certification application.
CannaPharmaRx (CPMD) filed its Q3 2025 report, showing rising sales but continued losses and severe liquidity strain. Revenue reached $656,606 in the quarter (up from $312,164), yet the company posted a gross loss of $440,000 and a net loss of $1,477,811. For the nine months, revenue was $1,223,533 with a net loss of $3,581,863. Cash was $927, total liabilities were $34,133,650, and shareholders’ deficit was $22,516,743. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
On August 7, 2025, the company formalized repayment plans with Koze and affiliates and with Mr. Tal: as of June 30, 2025, about $10 million was owed to Koze and about $0.7 million to Mr. Tal, with interest revised to 6% per annum and 60% of all future profits and capital raised allocated toward repayment. The company is also in default under a royalty/security agreement tied to cannabis sales; Koze agreed to forbear until December 31, 2025. Operations rely on a Formosa lease, with unpaid lease amounts accumulating and a related promissory note now at 6%. Shares outstanding were 662,501,405 as of November 14, 2025.
CannaPharmaRX, Inc. entered into letter agreements that set out payment schedules to address outstanding amounts owed to two significant debtholders. The company states that these schedules are intended to manage existing debt, avoid additional defaults, and still retain capital to grow operations and deliver product. The agreements and their terms had already been described in the company’s quarterly report for the period ended June 30, 2025, but the actual schedule documents were mistakenly omitted. This report is being used to file those repayment schedule agreements as exhibits so they are formally included in the public record.